Therabron Therapeutics Appoints Global Pulmonary Experts to the Company's Scientific Advisory Board

ROCKVILLE, Md., May 19, 2016 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, announced today the appointment of four world-renowned experts to the company's newly created Scientific Advisory Board (SAB). Members of the Board will serve as a key resource to Therabron as the company pursues the development and ultimate commercialization of new therapies to treat a range of neglected and underserved respiratory conditions.

"We are honored to have such a noteworthy and distinguished group of pulmonary experts join Therabron's SAB, and we look forward to leveraging their extensive expertise as we work to advance our novel drug pipeline through the clinic and into the market," stated Thomas F. Miller, President and Chief Executive Officer of Therabron Therapeutics.

Dr. Gerard J. Criner
Dr. Criner, Chair and Professor of Thoracic Medicine and Surgery at Temple University School of Medicine, specializes in lung volume reduction surgery, respiratory muscle function, mechanical ventilation, advanced lung disease and lung transplantation. During his tenure at Temple, Dr. Criner has been instrumental in the development and success of the Department of Pulmonology and Critical Care Medicine, which has consistently ranked as one of the top programs in the nation.

An internationally recognized researcher, Dr. Criner presents globally at academic conferences. As principal investigator and project leader of several multimillion-dollar National Institutes of Health (NIH) grants, he has overseen numerous advances in pulmonary and critical care research over his academic career. Dr. Criner is recognized as a worldwide expert on Chronic Obstructive Pulmonary Disease (COPD) and the management of intensive-care unit patients.

Dr. Criner earned his medical degree from Temple University School of Medicine, where he also completed his residency. He completed a Fellowship at Boston University School of Medicine and was on faculty at the University of Maryland. Dr. Criner is author or co-author of over 200 peer-reviewed research articles, and a member of several professional societies, including Alpha Omega Alpha, American College of Chest Physicians, American Thoracic Society, Massachusetts Medical Society, Society of Critical Care Medicine, American Physiology Society, and the American College of Physicians.

Dr. Steven M. Donn

Dr. Donn is internationally known for his expertise in the management of respiratory failure in newborns and currently serves as Professor of Pediatrics at C.S. Mott Children's Hospital, part of the University of Michigan Health System. For 12 years he served as Director of the Division of Neonatal-Perinatal Medicine. He obtained his medical degree from Tulane University, and undertook training in General Pediatrics at the University of Vermont-Medical Center Hospital of Vermont. After completing his Fellowship in Neonatal-Perinatal Medicine at the University of Michigan, Dr. Donn remained and joined the faculty as an Assistant Professor of Pediatrics, and later became Medical Director of the Holden Neonatal Intensive Care Unit. 

Dr. Donn is actively involved in teaching, research and patient care activities and is a member of numerous professional societies including elected memberships in the Society for Pediatric Research, the European Society for Pediatric Research and the American Pediatric Society. He is a Fellow of the American Academy of Pediatrics and chaired its national Committee on Medical Liability and Risk Management. Dr. Donn has authored more than 220 medical journal articles, edited 32 books and specialty journals, written more than 200 book chapters and has produced numerous educational materials. 

Dr. Mario Castro, MPH, FCCP

Dr. Castro is Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine, and Professor, Medicine and Pediatrics, Division of Pulmonary and Critical Care Medicine at the Washington University School of Medicine in St. Louis, MO. He is affiliated with Barnes-Jewish Hospital in St. Louis. Dr. Castro's specialties include asthma and related allergic disease, COPD, emphysema, chronic bronchitis, chronic cough and unexplained shortness of breath. Dr. Castro is active in research and is currently working, under several grants from the NIH regarding the causes of asthma, especially severe asthma, as part of the Severe Asthma Research Program. He is the Principal Investigator of several networks sponsored by the NIH, Patient-Centered Outcomes Research Institute and American Lung Association, evaluating the management and treatment of asthma and airway diseases.

Dr. Castro received his medical degree from the University of Missouri - Kansas City School of Medicine.  He completed his Fellowship in Pulmonary/Critical Care, and his Residency in Internal Medicine, at the Mayo Clinic and earned a graduate degree in Public Health from St. Louis University School of Public Health. He is the recipient of numerous awards and is author or co-author of more than 200 peer-reviewed articles. Dr. Castro is Board Certified in Pulmonary Disease, Internal Medicine and Critical Care Medicine.

Dr. Martin R. Zamora

Dr. Zamora is Professor of Medicine and Medical Director Lung Transplant Program, Pulmonary Sciences and Critical Care Medicine at the University of Colorado Denver – Anschutz Medical Campus in Aurora, CO.  He joined the Division of Pulmonary Sciences and Critical Care Medicine more than 25 years ago and has been the directing pulmonologist for the lung transplant program since its beginning in 1991. He is also a United Network for Organ Sharing (UNOS) certified lung transplant doctor.

Dr. Zamora is widely published, in both clinical and basic research fields, and is regarded as a world expert on lung transplantation and viral infection complications -- in particular -- cytomegalovirus. The goal of his research, via The Zamora Lab, is to investigate some of the causes of lung ischemia-reperfusion injury and to find ways in which to alleviate the injury. The lab is also investigating novel ways to abrogate mechanisms of rejection.

Dr. Zamora received his medical degree from the University of Colorado Medical School, where he also completed his Internship, Residency and Fellowship training. He is Board Certified in Critical Care, Internal and Pulmonary Medicine.

About Therabron Therapeutics, Inc.

At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins, which includes the CC10 protein — a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class biologic therapeutics. For additional information, please visit www.therabron.com.

SOURCE Therabron Therapeutics, Inc.

Related Links

http://www.therabron.com